Skip to main content
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. — Investor Relations & Filings

Ticker · SMMT ISIN · US86627T1088 US Manufacturing
Filings indexed 527 across all filing types
Latest filing 2025-11-07 Regulatory Filings
Country US United States of America
Listing US SMMT

About Summit Therapeutics Inc.

https://www.smmttx.com/

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for serious unmet medical needs, with a primary focus on oncology. The company's mission is to improve the quality and potential duration of life for patients. Its lead product candidate is ivonescimab (SMT112), a novel bispecific antibody that targets both PD-1 and VEGF. Summit is advancing ivonescimab through multiple global Phase III clinical trials to treat various solid tumors, with a significant emphasis on non-small cell lung cancer (NSCLC). The company's strategy centers on developing innovative treatments that can provide substantial benefits for patients, physicians, and caregivers.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2025-11-07 English
S-3ASR
Regulatory Filings
2025-10-29 English
FORM 4
Director's Dealing
2025-10-24 English
FORM 4
Director's Dealing
2025-10-23 English
FORM 4
Director's Dealing
2025-10-23 English
FORM 4
Director's Dealing
2025-10-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.